Patent · US Active

Therapy

US12121593B2 · kind B2 · utility

0Cited by
1References
16Claims
0Family size

Assignee

Inventors

Key dates

Filing dateJun 15, 2021
Grant dateOct 22, 2024
Priority date—
Expiry dateSep 15, 2041

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC12N2830/50
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The application provides gene therapies for treating monogenic forms of nephrotic syndrome.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.